Article citationsMore>>

C. Zhou, Y. L. Wu, G. Chen, et al., “Erlotinib versus Chemotherapy as First-Line Treatment for Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (OPTIMAL, CTONG-0802): A Multicentre, Open-Label, Randomised, Phase 3 Study,” Lancet Oncology, Vol. 12, No. 8, 2011, pp. 735-742. doi:10.1016/S1470-2045(11)70184-X

has been cited by the following article: